

Dr. med. Simone Edenhofer – Publikationsliste

CLL2-GIVe, a prospective, open-label, multicenter phase-II trial of obinutuzumab, ibrutinib, plus venetoclax in untreated patients with CLL with 17p deletion / *TP53* mutation. Henriette Huber, **Simone Edenhofer**, Julia von Tresckow, Michaela Grimm, Can Zhang, Sandra Robrecht, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten Niemann, Michael Kneba, Johannes Bloehdorn, Christof Schneider, Eugen Tausch, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer. EHA-2275. 2020

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature. Jennifer Jeck, Rebecca Kassubek, Jan Coburger, **Simone Edenhofer**, Stefan S. Schönsteiner, Albert C. Ludolph, Bernd Schmitz, Jens Engelke, Regine Mayer-Steinacker, Jan Lewerenz, and Lars Bullinger. Ther Adv Neurol Disord. 2018; Jan 21;11:1756285617753597.

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia. Henriette Huber, **Simone Edenhofer**, Sven Estenfelder, and Stephan Stilgenbauer. Onco Targets Ther. 2017; Feb 7;10:645-656.

Chronic Lymphocytic Leukemia With TP53 Aberrations: Breakthroughs and Challenges. **Simone Edenhofer** and Stephan Stilgenbauer. Journal of Oncology Practice 2017; Jun;13(6):381-382.

Activity of cabazitaxel in temozolomide refractory glioblastoma: Final results of a phase 2 study (C-GBM study; EudraCT 2013-001550-98 NCT 01866449). Bernhard Heinrich, Richard F Schlenk, Olaf Lothar Brudler, **Simone Edenhofer**, Angelika Scheuerle, Ralph Naumann, Regine Mayer-Steinacker, Markus Bangerter, Lars Bullinger. Journal of Clinical Oncology 2017. 35(15_suppl):2056-2056.